Vol. 6 No. 9 (2026): September
Reimbursement Reviews

Sarilumab (Kevzara)

decorative image of the issue cover

Published September 2, 2026

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses sarilumab (Kevzara), 150 mg/1.14 mL or 200 mg/1.14 mL, as a single-dose prefilled syringe or prefilled pen, subcutaneous injection.
  • Indication: Sarilumab injection is indicated in the treatment of adult patients with polymyalgia rheumatica (PMR) who have had an inadequate response to corticosteroids, or who have experienced a relapse during corticosteroid taper.